Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Vaccines

Free Subscription 25.05.2026 1 BMC Pediatr 1 BMJ 2 J Infect 1 J Infect Dis 3 J Virol 1 N Engl J Med 1 Nat Immunol 2 Nat Med 7 PLoS One 3 Proc Natl Acad Sci U S A 1 Science 21 Vaccine 1 Virology 2 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Pediatr

1. JARSO H, Yohannes D, Gebru T, Kebebe L, et al
   Incomplete vaccination among children aged 12-35 months in West Arsi Zone, Ethiopia.
   BMC Pediatr. 2026 May 22. doi: 10.1186/s12887-026-07020.
   PubMed         Abstract available
   
   

   
   BMJ

2. BARANIUK C
   Ebola: WHO declares emergency as strain with no vaccine kills 100 in DRC and Uganda.
   BMJ. 2026;393:e313572.
   PubMed        
   
   

   
   J Infect

3. MUNRO AP, Ferrari M, Kinsley R, Egan D, et al
   A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.
   J Infect. 2026 May 18:106759. doi: 10.1016/j.jinf.2026.106759.
   PubMed         Abstract available
   
   
4. HUTTON MM, Vink PE, Kuxhausen A, Tsang M, et al
   Long-term immunogenicity and safety of RZV primary vaccination and revaccination in kidney transplant recipients.
   J Infect. 2026 May 14:106758. doi: 10.1016/j.jinf.2026.106758.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. MUELLER BROWN K, Kindsvogel AM, Petnuch SE, Freeman TL, et al
   Live-attenuated Rift Valley fever virus vaccination leads to durable, protective immunity independent of sex in C57BL/6 mice.
   J Infect Dis. 2026 May 15:jiag266. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

6. ZHOU C, Cheng M-L, He M-J, Liu Y, et al
   MicroRNA-124-targeted recombinant Zika virus: a dual-functional and safe candidate for vaccination and oncolytic virotherapy.
   J Virol. 2026 May 15:e0020826. doi: 10.1128/jvi.00208.
   PubMed         Abstract available
   
   
7. NASIR A, Lee D, Avena LE, Berrueta DM, et al
   Predictive modeling of immune escape and antigenic grouping of SARS-CoV-2 variants.
   J Virol. 2026 Apr 27:e0022526. doi: 10.1128/jvi.00225.
   PubMed         Abstract available
   
   
8. YILDIZ S, El Zahed SS, Villalon-Letelier F, Wang Q, et al
   Re-engineering segment 8 facilitates generation of a versatile live-attenuated influenza A virus vector platform for secretory protein delivery.
   J Virol. 2026 Apr 21:e0034726. doi: 10.1128/jvi.00347.
   PubMed         Abstract available
   
   

   
   N Engl J Med

9. O'LEARY ST, Danchin M
   Childhood Vaccine Hesitancy.
   N Engl J Med. 2026 May 20. doi: 10.1056/NEJMcp2516616.
   PubMed         Abstract available
   
   

   
   Nat Immunol

10. PECETTA S, Andreano E, Rappuoli R
    Broadly protective mucosal vaccination in the respiratory tract.
    Nat Immunol. 2026 May 19. doi: 10.1038/s41590-026-02530.
    PubMed        
    
    

    
    Nat Med

11. KIM JH, Ndembi N
    Global vaccine development.
    Nat Med. 2026;32:1610-1622.
    PubMed         Abstract available
    
    
12. CANFELL K
    HPV vaccines, 20 years on.
    Nat Med. 2026;32:1583-1585.
    PubMed        
    
    

    
    PLoS One

13. MUBANGA C, Mubanga M, Chilyabanyama ON, Phiri M, et al
    Evaluation of plasma anti-CS3 and anti-LTB IgG avidity among Zambian children vaccinated with ETVAX.
    PLoS One. 2026;21:e0335327.
    PubMed         Abstract available
    
    
14. PALOMBO CNT, Souza EA, Garcia EM, da Silva Araujo RP, et al
    Vaccine confidence and hesitancy among mothers of children under six years of age in Salvador, Brazil: The role of sociodemographic factors and health service experience.
    PLoS One. 2026;21:e0344742.
    PubMed         Abstract available
    
    
15. VISKUPIC F, Daly R, Wiltse DL, Gonda M, et al
    The relationship between personal COVID-19 vaccination decisions and cattle vaccination practices: Evidence from a survey of South Dakota beef producers.
    PLoS One. 2026;21:e0349234.
    PubMed         Abstract available
    
    
16. RIOS MONTOYA V, Suarez Alarcon AY, Perez Castillo S, Zamudio Raez T, et al
    Beyond coverage: Can vaccination reduce child mortality despite structural inequality? A global ecological analysis of routine childhood immunization (2010-2023).
    PLoS One. 2026;21:e0340756.
    PubMed         Abstract available
    
    
17. ESSAYAGH T, Essayagh M, Slibani H, El Hachimi S, et al
    Challenges to human papillomavirus vaccination among young girls in Morocco: A national cross-sectional study.
    PLoS One. 2026;21:e0347783.
    PubMed         Abstract available
    
    
18. 
    Retraction: SARS-CoV2 mRNA vaccine intravenous administration induces myocarditis in chronic inflammation.
    PLoS One. 2026;21:e0349831.
    PubMed        
    
    
19. HURTADO-SALGADO E, Lazcano-Ponce E, Romero-Martinez M, Terrazas-Medina EA, et al
    Knowledge, attitudes, and practices related to adult vaccination among adults and healthcare professionals across Mexico.
    PLoS One. 2026;21:e0348625.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

20. ZHANG J, Zhang X, Yao Y, Zhou J, et al
    Multivalent mRNA vaccine platform with compatible antigens conferred broad-spectrum protection against orthoebolaviruses' exposure.
    Proc Natl Acad Sci U S A. 2026;123:e2517814123.
    PubMed         Abstract available
    
    
21. XIAO Z, Xu H, Ma N, Lei L, et al
    A BCG hydrogel enables localized NOD2/STING activation to overcome resistance to immune checkpoint blockade.
    Proc Natl Acad Sci U S A. 2026;123:e2531588123.
    PubMed         Abstract available
    
    
22. DOOKIE R, Narciso AR, Gaytan MO, Narayana Moorthy A, et al
    Pneumococcal membrane particles promote serotype-independent cellular and humoral immunity and protect against pneumococcal colonization.
    Proc Natl Acad Sci U S A. 2026;123:e2537226123.
    PubMed         Abstract available
    
    

    
    Science

23. KUPFERSCHMIDT K
    Scientists play catch-up to startling Ebola outbreak.
    Science. 2026;392:792-793.
    PubMed         Abstract available
    
    

    
    Vaccine

24. RANQUE B, Galtier F, Nunes H, Le Jeunne C, et al
    Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.
    Vaccine. 2026;86:128732.
    PubMed         Abstract available
    
    
25. HARMA V, Palsola M, Kuusipalo A, Lindh E, et al
    Lessons from the 2024 avian influenza vaccination campaign in Finland: a qualitative inquiry.
    Vaccine. 2026;86:128736.
    PubMed         Abstract available
    
    
26. TANG Q, Li J, Hou C, Qiu Z, et al
    Optimization of chicory root polysaccharide liposomes and their adjuvant efficacy in Newcastle disease vaccination.
    Vaccine. 2026;86:128734.
    PubMed         Abstract available
    
    
27. HURST DJ, Bobier CA, Coleman M, Streeks-Wooden N, et al
    Presumptive recommendations and informed consent in pediatric vaccination.
    Vaccine. 2026;86:128747.
    PubMed        
    
    
28. FORNS J, Pajouheshnia R, Aurelius T, Bouck Z, et al
    Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study.
    Vaccine. 2026;86:128723.
    PubMed         Abstract available
    
    
29. POWELL A, Suwalowska H, Sankoh O, Guo C, et al
    Recent enough to matter: Perceived temporal proximity, anxiety, and COVID-19 vaccine intent.
    Vaccine. 2026;85:128717.
    PubMed         Abstract available
    
    
30. DALEXIS RD, Beogo I, Kibret TC, Cenat JM, et al
    Racial disparities in coverage and determinants of childhood diphtheria, tetanus, and pertussis (DTaP) vaccination in Canada: a post-COVID-19 pandemic analysis.
    Vaccine. 2026;85:128679.
    PubMed         Abstract available
    
    
31. CABURNAY CA, Fu QJ, Carter T, Butler T, et al
    Identification of best outreach strategies and delivery modalities for population subgroups for COVID-19 vaccination.
    Vaccine. 2026;60 Suppl 1:128721.
    PubMed         Abstract available
    
    
32. MALHOTRA G, Bilguche A, Eades O, Loftus MJ, et al
    Coverage and missed opportunities for routine vaccination in adult travellers: a single-centre observational study.
    Vaccine. 2026;86:128735.
    PubMed         Abstract available
    
    
33. BETTINA H, Anna SJ, Reinhard K
    A chimeric L1-L2 virus-like particle (VLP) vaccine targeting common cutaneous human papillomavirus type 1 (HPV1).
    Vaccine. 2026;86:128729.
    PubMed         Abstract available
    
    
34. KOHLI M, Maschio M, Lee A, Kissler S, et al
    The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission model.
    Vaccine. 2026;85:128687.
    PubMed         Abstract available
    
    
35. ISHOSO DK, Fandema E, Hoff NA, Nkamba DM, et al
    Dropout from the pentavalent vaccine series among children aged 12-23 months in the Central African Republic: prevalence, associated factors, and caregiver-reported barriers.
    Vaccine. 2026;85:128700.
    PubMed         Abstract available
    
    
36. CHEN M, Zhang X, Yao Y, Yu J, et al
    Complete protection against lethal Nipah virus challenge by intranasal vaccination with bacteriophage T4 coupled with Nipah virus G or F protein.
    Vaccine. 2026;85:128727.
    PubMed         Abstract available
    
    
37. SUN X, Liu R, Yang H, Zhang Y, et al
    A nanoparticle vaccine targeting glycoprotein D induces immune protection against pseudorabies virus.
    Vaccine. 2026;85:128704.
    PubMed         Abstract available
    
    
38. CAO T, Chen B, Chen S, Liu H, et al
    Instruments for measuring parents' vaccine hesitancy towards their children based on the COSMIN guidelines: A systematic review.
    Vaccine. 2026;85:128703.
    PubMed         Abstract available
    
    
39. NUWAGABA-BIRIBONWOHA H, Lamb MR, Dlamini X, Zerbe A, et al
    Immunogenicity of 2 versus 3 dose HPV vaccination by HIV infection status in Eswatini.
    Vaccine. 2026;85:128692.
    PubMed         Abstract available
    
    
40. ZENG L, Pan D, Huang Y, Luo D, et al
    Double proline- substituted porcine epidemic diarrhea virus full-length spike mRNA vaccine confers enhanced immunogenicity and protective efficacy compared to conventional inactivated vaccine.
    Vaccine. 2026;85:128699.
    PubMed         Abstract available
    
    
41. TRANG TPH, Bazelier MT, Klungel OH, Bots SH, et al
    Quality and methodological heterogeneity of COVID-19 vaccine safety studies focusing on the myocarditis safety signal: A systematic review, meta-analysis and meta-regression.
    Vaccine. 2026;85:128722.
    PubMed         Abstract available
    
    
42. XU Y, Nyberg F, Marking U, Gisslen M, et al
    Rare adverse events after COVID-19 vaccination among Swedish older adults-evidence from a nationwide register-based study.
    Vaccine. 2026;85:128724.
    PubMed         Abstract available
    
    
43. WILSON LF, Dobson AJ, Mishra GD
    Associations between childhood adversity and human papillomavirus vaccination in Australian women: a cross-sectional study.
    Vaccine. 2026;85:128719.
    PubMed         Abstract available
    
    
44. SHAPIRO I, Tadese BK, Hoshen M, Chen YT, et al
    Corrigendum to "A significant decrease in anogenital warts incidence following the implementation of a national human papillomavirus immunization program in Israel" [Vaccine 80 (2029) 128516].
    Vaccine. 2026;85:128695.
    PubMed        
    
    

    
    Virology

45. BEHNEZHAD F, Ataei-Pirkooh A, Kachooei A, Golsaz-Shirazi F, et al
    The rotavirus cVLP(VP8 *) vaccine candidate induces cross-genotype/heterotypic neutralizing antibody responses against human rotavirus G9P[4].
    Virology. 2026;621:110957.
    PubMed         Abstract available
    
    

    
    Virus Res

46. VALENZUELA-FUENZALIDA JJ, Velarezco LM, Silva V, Delgado F, et al
    Occurrence of Myocarditis in Patients Immunized with Different Types of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.
    Virus Res. 2026 May 20:199748. doi: 10.1016/j.virusres.2026.199748.
    PubMed         Abstract available
    
    
47. AGGAD WS, Mishra SK, Alqahtani T, Guendouzi A, et al
    Epitope-based vaccine of NiV targeting glycoprotein and fusion protein: an integrated immunoinformatics and bioinformatics approach.
    Virus Res. 2026;369:199746.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum